Mylatabi (Eltrombopag)

Eltrombopag, the active ingredient in Mylatabi, is a thrombopoietin receptor agonist presented as an oral formulation for oral use. It is indicated for chronic immune thrombocytopenia, aplastic anemia, and severe thrombocytopenia associated with hepatitis C in appropriate patients.

GNH USA supplies Mylatabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company emphasizes strict quality assurance and compliance with global regulatory standards. Mylatabi is distributed to a broad network of healthcare providers across Europe, Asia and the Americas.

Eltrombopag is used to manage disorders characterized by low platelet production.

- Chronic immune thrombocytopenia (ITP): Increases platelet counts to reduce bleeding risk. - Aplastic anemia: Stimulates megakaryocyte development to improve platelet numbers in bone‑marrow failure. - Severe thrombocytopenia associated with hepatitis C: Enhances platelet production to support antiviral therapy and reduce hemorrhagic complications.

Eltrombopag may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Diarrhea: loose stools, usually transient. - Fatigue: generalized tiredness. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Thromboembolic events: blood clots such as deep vein thrombosis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bone marrow fibrosis: rare progression affecting marrow architecture.

When prescribing Eltrombopag, clinicians should consider several safety precautions.

- Liver function monitoring: check ALT/AST before and during therapy. - Blood counts: regular platelet and complete blood count assessments. - Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited. - Drug interactions: avoid concomitant use with strong CYP3A4 inducers without adjustment. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Eltrombopag can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure. - Antacids containing polyvalent cations (e.g., calcium, magnesium): can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may increase plasma levels, requiring dose adjustment. - Warfarin: potential alteration of INR, necessitating closer coagulation monitoring. - Live vaccines: reduced immune response, consider timing of administration.